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Introduction
Lung transplantation (LTx) is the only treatment option 
for patients with end stage lung disease whose respiratory 
function is declining. Many candidates for LTx suffer from 
chronic disease and two thirds of them have reduced muscle 
mass (1). Maintaining skeletal muscle mass and strength 
seems to be essential for patients to recover after LTx (2-4).
Sarcopenia, which can be defined as low muscle mass 
and associated decreased muscle strength or function (5), 
leads to physical disabilities, poor quality of life, and death 
in older patients. Sarcopenia has also been reported to be 
associated with a poor survival outcome following liver (6) 
and renal (7) transplantation. In chronic lung disease 
patients, quadriceps strength (8), body composition (9), 
and mid-thigh cross sectional area (CSA) (10) have been 
reported to be related to mortality.
Several modalities have been used to assess sarcopenia. 
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Computed tomography (CT) (10), magnetic resonance 
imaging (MRI) (11), bioelectrical impedance (BIA) (12), 
anthropometry (13), and dual-energy X-ray absorptiometry 
(DXA) (14) have been used to assess muscle mass, while 
handheld and computerized dynamometry have been used 
to measure hand grip and quadriceps strength (3,15). Short 
Physical Performance Battery and usual gait speed can 
assess functional status (16-18). The 6-minute walk test 
is the most commonly used modality to assess functional 
status but it cannot index isolated muscle function as part of 
the sarcopenia definition (5).
Some studies of LTx patients have focused on low muscle 
mass and the importance of rehabilitation after LTx (3,4), 
but the clinical effect of sarcopenia on LTx outcome has not 
been studied until now. In this study, we hypothesized that 
thoracic skeletal muscle mass measured by analyzing the 
CSA from a chest CT image could be a predictor of early 
outcomes and survival after LTx, and can also be used to 
assess the suitability of lung transplant candidates.
Methods
Patients
This study was approved by the Severance Hospital 
Institutional Review Board (4-2016-0129). We retrospectively 
reviewed the medical records of 111 patients who underwent 
LTx at our institution between January 2010 and July 2015. 
Age, sex, underlying diseases, height and weight at the time 
of the operation, post-operative course and mortality data 
were collected for all patients; data on thoracic muscle CSA 
were available in 109 of the patients. 
Measurement of thoracic skeletal muscle CSA
The thoracic muscle CSA at the level of the carina was 
determined based on a study performed by Rozenberg et al. (19). 
The first single slice identifying at carina level on each 
patient’s chest CT scan was selected. We then outlined 
the borders of the thoracic skeletal muscle (pectoralis, 
intercostal and paraspinal muscles) in the CSA, and the area 
was measured (Figure 1). These steps were completed semi-
automatically using Aquarius iNtuition Viewer (ver. 4.4.11, 
TeraRecon Inc., San Mateo, CA, USA). A radiology 
technician performed these steps without access to patient 
information.
Statistical analysis
Statistical analysis was performed using Student’s t-test 
or ANOVA (two-tailed) and the chi-square test. The 
correlation between the CSA and body mass index (BMI) 
was analyzed using Pearson’s correlation coefficient. 
Survival was analyzed with the Kaplan-Meier method. 
The Log-rank test was used to determine statistical 
significance. Multivariate analysis was performed using the 
Cox proportional hazards regression model to investigate 
the effects of several variables on survival. The criterion for 
statistical significance was P<0.05. SPSS software (ver. 20.0; 
SPSS Inc., Chicago, IL, USA) was used to perform the 
analyses.
Results
There were 48 female and 61 male patients, with a mean 
age of 49.7±13.9 years (range, 16–75 years). Patient 
characteristics are summarized in Table 1. The mean CSA 
was 58.2±15.8 cm2 (range, 25.4–93.3 cm2). The median 
interval between the date of the CT scan and the date 
of LTx was 2 months (range, 0–20 months). The scatter 
diagram in Figure 2 shows that the CSA and BMI were 
positively correlated (r=0.367, P<0.001). 
We divided the patients into four groups according to 
CSA to visualize the effects of both the highest and lowest 
quartile CSA (Table 2). Patients in the highest CSA quartile 
(Q4; 79.7±6.7) were more likely to be male (92.6% vs. 
17.9%, P<0.001) and older (55.2±10.1 vs. 43.2±14.9 years, 
P=0.001), to have a higher BMI (22.3±4.0 vs. 19.4±3.7 kg/m2, 
P=0.007) and to have more pulmonary fibrosis (85.2% vs. 
35.7%, P=0.003) compared with the lowest CSA quartile 
(Q1; 39.4±5.2) (Table 2).
Figure 1 Thoracic muscle cross sectional area (CSA) was measured 
by using outline of pectoralis, intercostal and paraspinal muscles in 
chest computed tomography at the carina from caudal (the white 
arrow indicated thoracic muscles).
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Early post-operative recovery times including ventilator 
support duration (32.9±49.1 vs. 24.5±39.5 days, P=0.488), 
intensive care unit (ICU) stay duration (28.4±43.7 vs. 
24.4±35.9 days, P=0.714) and hospital stay duration 
(61.4±48.2 vs. 50.8±37.2 days, P=0.367) showed longer 
trends in Q1 compared with Q4, but the difference was 
not significant. Early (≤30 days) mortality (7.1% vs. 11.1%, 
P=0.669) and 90 days mortality (28.6% vs. 29.6%, P= ns) 
were not different between Q1 and Q4 (Table 3). 
Survival was analyzed according to CSA quartile. The 
highest CSA (Q4) showed poorer survival compared to 
sarcopenia (Q1; P=0.044), Q2 (P=0.094) and Q3 (P=0.583). 
When Q4 was compared to the other groups simultaneously 
(Q1, Q2, Q3), poorer survival times were noted, but the 
difference was not statistically significant (P=0.063) (Figure 3). 
Sarcopenia (Q1) was not a risk factor for survival.
Discussion
The first human LTx was performed in 1963 (20), and the 
first successful LTx was reported in 1983 (21). Thereafter, 
the quantity of LTx operations has increased significantly, 
and 3,893 adult LTx procedures were performed worldwide 
in 2013 (22). LTx is the only therapeutic option available 
to patients with end-stage lung diseases of various 
nonmalignant etiologies in whom medical therapy has 
failed. Survival following LTx has steadily increased over 
time, and risk factors for early and late outcomes have been 
studied to improve survival.
Many transplant recipient factors, such as old age, 
type of disease, increased severity of illness (e.g., ICU 
stay, ventilator support), lower cardiac output and higher 
creatinine levels have been identified as risk factors for 
increased mortality in the International Society for Heart 
and Lung Transplantation (ISHLT) Registry (22).
BMI is considered a risk factor for death after LTx. 
Obesity and decreased body weight, which are defined 
using BMI, have been considered relative contraindications 
for LTx (23,24). In previous studies, obesity (BMI greater 
than 30 kg/m2) was considered a relative contraindication 
to LTx (25), and these patients had a marked decrease in 
post-transplantation survival rate (26). A recent study 
suggested that higher levels of plasma leptin and adipose 
tissue were detected in patients with obesity, factors that 
may be associated with primary graft dysfunction (27). 
Therefore, obesity was associated with an increased 
mortality rate after LTx. However, another study suggested 
that obesity is not associated with 1-year mortality after 
LTx, and a BMI greater than 30 kg/m2 may no longer 
represent a contraindication (28). Overall, controversy 
surrounds interpretation the relationship between obesity 
and survival rates in LTx patients.
In addition, the relationship between low body mass and 
a poor outcome after LTx has not been fully elucidated. 
In order to explain this problem, sarcopenia has emerged 
as a potential risk factor (2,23), but it is not clear whether 
sarcopenia is an independent risk factor for survival.
Table 1 Recipient characteristics
Variables Data
Age, years 49.7±13.9 (16.0–75.0)
Male 61 (56.0)
Body mass index, kg/m2 20.6±3.9 (12.3–33.5)
Cross sectional area, cm2 58.2±15.8 (25.4–93.3)
Disease entity
Pulmonary fibrosis 73 (67.0)
Bronchiolitis obliterans 13 (11.9)
Bronchiectasis 10 (9.2)
Lymphangioleiomyomatosis 9 (8.3)
Other 4 (3.6)
Transplant type
Single 10 (9.2)
Double 99 (90.8)
Data are presented as number of patients (%) or mean ± standard 
deviation (range).
Figure 2 Scatter diagram demonstrating the correlation between 
thoracic muscle mass cross sectional area (cm2) and body mass 
index (kg/m2). A positive relationship is noted (r=0.367, P<0.001).
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Sarcopenia has been defined as decreased muscle mass 
and peripheral muscle strength or function (5). However, 
exact definition of sarcopenia and standardized measurement 
techniques have not yet been established in LTx patients (2). 
Several methods of measuring sarcopenia have been used 
to assess muscle mass (quadriceps, triceps), muscle strength 
(quadriceps strength, hand-grip strength) and muscle 
function in patients with lung disease (5,29). In this study, 
sarcopenia of thoracic skeletal muscles was assessed by 
analyzing a CSA from chest CT images and defined as the 
lowest quartile of CSA (Q1). 
Sarcopenia (quadriceps strength) is a risk factor for 
survival in patients with chronic obstructive pulmonary 
disease (COPD) (8), and patients treated with LTx showed 
similar changes in muscle mass and strength to patients with 
COPD (11). Furthermore, sarcopenia has been associated 
Table 2 Characteristics according to cross sectional area (CSA)
Variables Q1 (n=28) Q2 (n=27) Q3 (n=27) Q4 (n=27) P value (Q1 vs. Q4)
Age, years 43.2±14.9 46.3±15.3 54.3±10.9 55.2±10.1 0.001
Male 5 (17.9) 9 (33.3) 22 (81.5) 25 (92.6) <0.001
Body mass index, kg/m2 19.4±3.7 20.0±3.5 20.8±3.8 22.3±4.0 0.007
CSA, cm2 39.4±5.2 51.3±3.5 63.3±6.7 79.7±6.7 <0.001
Disease entity 0.003
Pulmonary fibrosis 10 (35.7) 18 (66.7) 22 (81.5) 23 (85.2)
Bronchiolitis obliterans 5 (17.9) 4 (14.8) 2 (7.4) 2 (7.4)
Bronchiectasis 6 (21.4) 0 3 (11.1) 1 (3.7)
Lymphangioleiomyomatosis 5 (17.9) 4 (14.8) 0 0
Other 2 (7.1) 1 (3.7) 0 1 (3.7)
Transplant type ns
Single 2 (7.1) 1 (3.7) 6 (22.2) 1 (3.7)
Double 26 (92.9) 26 (96.3) 21 (77.8) 25 (92.6)
Data are presented as number of patients (%) or mean ± standard deviation (range). Q, quartile; ns, not significant.
Table 3 Intraoperative data and early outcomes
Variables Q1 (n=28) Q2 (n=27) Q3 (n=27) Q4 (n=27) P value (Q1 vs. Q4)
Pre-operative support
ECMO 7 (25.0) 4 (14.8) 4 (14.8) 4 (14.8) 0.503
Ventilator 12 (42.9) 6 (22.2) 7 (25.9) 8 (29.6) 0.582
Intra-operative ECLS support 0.135
CPS 5 (17.9) 6 (22.2) 7 (25.9) 7 (25.9)
ECMO 17 (60.7) 20 (74.1) 17 (63.0) 19 (70.4)
Ischemic time before 1st graft, min 227.1±64.8 225.4±82.3 231.7±79.6 247.1±111.3 0.416
Post-operative support
ECMO 8 (28.6) 13 (48.1) 8 (29.6) 12 (44.4) 0.269
Ventilator, day 32.9±49.1 12.1±13.9 18.3±25.0 24.5±39.5 0.488
Intensive care unit stay, day 28.4±43.7 13.9±13.2 21.9±21.4 24.4±35.9 0.714
Hospital stay, day 61.4±48.2 50.1±49.9 45.9±35.1 50.8±37.2 0.367
30 days mortality 2 (7.1) 4 (14.8) 6 (22.2) 3 (11.1) 0.669
Data are presented as number of patients (%) or mean ± standard deviation. Q, quartile; ECMO, extracorporeal membrane oxygenator; 
ECLS, extracorporeal life support; CPS, cardiopulmonary support.
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with poor post-transplantation outcomes in liver and renal 
transplant recipients (6,7), therefore, we hypothesize that it 
may negatively impact survival following LTx.
Previous studies on sarcopenia have focused on physical 
activity and rehabilitation in LTx patients, and the quadriceps 
muscle is mainly used in the context of skeletal muscle 
assessment (3,30-32). Thoracic muscles and major respiratory 
muscles have been surgically dissected; nevertheless, 
sarcopenia of thoracic muscles in LTx patients has not been 
fully evaluated. Recently, Rozenberg et al. (19) suggested 
that the thoracic muscle CSA is related to physical activity, 
quadriceps volume, and health-related quality of life after 
LTx, but survival was not assessed. Therefore, the present 
study was designed to investigate the relationship between 
thoracic sarcopenia and survival after LTx.
When we began our study, we assumed that thoracic 
sarcopenia was related to BMI, which would negatively affect 
the early outcomes (ventilator support, ICU stay, and hospital 
stay) and early survival. Like other muscles (quadriceps, 
triceps) (33), respiratory muscles have been correlated with 
BMI, as shown in Figure 2. Early survival tended to be longer 
in sarcopenia (Q1), but the difference was not statistically 
significant (Table 3). Also, the survival of LTx patients was not 
affected by sarcopenia (Q1); by contrast, Q1 was associated 
with better survival than Q4 (Figure 3).
The increased survival of Q1 compared with Q4 
after LTx may be explained as follows. The first possible 
explanation is that sarcopenia of the thoracic muscles 
may not be a modifiable risk factor. Quadriceps muscle 
atrophy can be caused by medications (corticosteroids or 
immunosuppressants) or inactivity after LTx (11,34), and 
rehabilitation leads to recovery of skeletal muscle function (3). 
Pinet et al. (34) reported that the diaphragm and abdominal 
respiratory muscle volume are preserved, but the quadriceps 
can atrophy, after transplantation (12 patients; 5 of whom 
underwent heart-LTx and 7 who underwent LTx). Thoracic 
muscles are constantly exercised by respiratory movements 
even on mechanical ventilation, and thus thoracic muscles 
may not atrophy similarly like the diaphragm or abdominal 
respiratory muscles. Therefore, we suggest that it may 
be more accurate to assess the quadriceps rather than the 
thoracic muscle to analyze survival in LTx patients.
Second, Q4 may be related to a high BMI. The thoracic 
muscle CSA showed a linear correlation with BMI (Figure 2), 
and a high BMI was a risk factor for LTx, although reports 
were controversial. Third, these results may be due to the 
heterogeneity of the patient population used in this study. 
In Q4, patients tended to be older males with pulmonary 
fibrosis (Table 2). However, these factors (age, sex, and 
diagnosis) were not independent risk factors for survival 
in subgroup multivariate analysis (data not shown). Lastly, 
there is no standard definition of sarcopenia, although in 
this study we defined it as Q1. Considering these possible 
causes, more studies are required to better understand 
sarcopenia of thoracic muscles in patients undergoing LTx.
The limitations of this study include its retrospective, single-
center design and clinically heterogeneous patient population. 
These limitations notwithstanding, it is important to note that 
the present study attempted to analyze the association between 
thoracic sarcopenia and outcome after LTx.
In conclusion, sarcopenia of thoracic muscle mass did 
not compromise either the early outcome or 1-year survival 
in LTx patients. More studies are needed to clarify the 
relationship between thoracic sarcopenia and outcomes in 
LTx patients.
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Figure 3 Kaplan-Meier curve shows that highest cross sectional 
area (CSA) Q4 showed poorer survival compared to Q1 (P=0.044) 
and Q2 (P=0.094) and Q3 (P=0.583). Also, Q4 had poorer survival 
than other groups together, but not statistically significant (Q4 vs. 
Q1 + Q2 + Q3, P=0.063).
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